Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

BACKGROUND: Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors. Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC). METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, D, Wong, R P W, D'Haens, G, Douillard, J-Y, Robertson, J, Stone, A M, Van Cutsem, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593537/
https://www.ncbi.nlm.nih.gov/pubmed/23299530
http://dx.doi.org/10.1038/bjc.2012.545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593537/
https://www.ncbi.nlm.nih.gov/pubmed/23299530
http://dx.doi.org/10.1038/bjc.2012.545

Ejemplares similares